Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 June 1997Website:
http://www.sarepta.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 41 min agoDividend
Analysts recommendations
Institutional Ownership
SRPT Latest News
Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025 and a potential BLA filing by mid-2025. Despite strong revenues, Sarepta may need to raise additional funds within the next 12 months to support ongoing operations and development programs from its pipeline.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Dallan Murray - Executive Vice President and Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Andrew Tsai - Jefferies Anupam Rama - JPMorgan Danielle Brill - Raymond James Eliana Merle - UBS Gil Blum - Needham & Company Ritu Baral - TD Cowen Joseph Schwartz - Leerink Partners Kostas Biliouris - BMO Capital Markets Brian Skorney - Baird Kristen Kluska - Cantor Fitzgerald Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore ISI Leo Watson - Mizuho Sami Corwin - William Blair Operator Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success on secondary measures like motor function improvement and time-to-rise. SRPT expects substantial revenue growth, projecting net product revenues of $2.9-3.1 billion by 2025.
Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.
Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.
Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.
What type of business is Sarepta Therapeutics?
Sarepta Therapeutics, Inc. is a biopharmaceutical corporation based in Cambridge, Massachusetts, specializing in medical research and the development of RNA-targeted therapeutic drugs for the treatment of rare diseases. It was founded in 1980. The company conducts clinical research and develops therapeutic drugs for a wide range of diseases. The company's product portfolio includes two approved commercial drugs: EXONDYS 51 - the first approved treatment targeting the underlying cause of Duchenne Muscular Dystrophy. VYONDYS 53 - a drug designed to treat Duchenne Muscular Dystrophy in patients with a mutation in the dystrophin gene (DMD).
What sector is Sarepta Therapeutics in?
Sarepta Therapeutics is in the Healthcare sector
What industry is Sarepta Therapeutics in?
Sarepta Therapeutics is in the Biotechnology industry
What country is Sarepta Therapeutics from?
Sarepta Therapeutics is headquartered in United States
When did Sarepta Therapeutics go public?
Sarepta Therapeutics initial public offering (IPO) was on 04 June 1997
What is Sarepta Therapeutics website?
https://www.sarepta.com
Is Sarepta Therapeutics in the S&P 500?
No, Sarepta Therapeutics is not included in the S&P 500 index
Is Sarepta Therapeutics in the NASDAQ 100?
No, Sarepta Therapeutics is not included in the NASDAQ 100 index
Is Sarepta Therapeutics in the Dow Jones?
No, Sarepta Therapeutics is not included in the Dow Jones index
When was Sarepta Therapeutics the previous earnings report?
No data
When does Sarepta Therapeutics earnings report?
The next expected earnings date for Sarepta Therapeutics is 28 February 2025